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Replacements*
David R. Holmes JR, MD,y Michael J. Mack, MDzT he concept of twofers is widely used ina variety of situations and applicationsranging from cabling devices in theatrical
stage lighting to Broadway tickets to 2 hamburgers
for a quarter at Tucker’s Twofers to items of
merchandise to something that “satisﬁes 2 criteria
or needs simultaneously.” The paper by Petronio
et al. (1), in this issue of JACC: Cardiovascular Inter-
ventions, takes this concept to a new level in the anal-
ysis of the relationship between the need for
permanent cardiac pacing (or consideration of it) in
the setting of a speciﬁc transaortic valve replacement
(TAVR) device, the Medtronic CoreValve (Medtronic,
Minneapolis, Minnesota).SEE PAGE 837This has been a contentious issue. In the surgical
arena of surgical aortic valve replacement, the
development of heart block requiring a pacemaker
is considered and reported as a complication and
typically occurs in 2% to 5% of patients. In contrast,
the ﬁeld of TAVR, as referenced in this paper,
report rates of pacemakers that vary widely from
10% to as high as 47% (2–6). There are device-
speciﬁc rates for the 2 most commonly used and
U.S. Food and Drug Administration–approved de-
vices in published registry experiences; one of the
speciﬁc manufacturer devices has typically been
associated with substantially higher rates of pace-
maker implantation than the other. This discrep-
ancy has raised the discussion of the deﬁnition of
what constitutes a “complication.” If the need for a*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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contents of this paper to disclose.pacemaker is considered to be a common and
accepted part of the procedure (a twofer), that has 1
set of implications; however, if a permanent pace-
maker is coded as a complication of TAVR, that has
important potentially negative implications, in
particular, for example, if 1 TAVR device has a
substantially higher rate. This has implications for
the reporting of complications for risk stratiﬁcation
and for reimbursement and may also have an
impact on patient decisions. This consideration has
led to changes in practice. It has been commented
on by some that perhaps sometimes these changes
may have been made to “game” the system; for
example, in some centers (by report), pacemakers
are implanted before the TAVR procedure so that
the need for a pacemaker does not need to be
recorded as a complication; in other cases, the
pacemaker is implanted later, more electively, again
to avoid the label of a “complication.”
The present study is an important one and eval-
uates several important issues: 1) the rate of new
permanent pacemaker implantation when placed
according to Class I or II indications recommended
by professional societies (7); 2) the relationship
of procedural variables with the subsequent need
for permanent pacemaker implantation; 3) the fre-
quency and time course of new conduction de-
fects; and 4) the safety and efﬁcacy of the TAVR
procedure.
A speciﬁc valve, the self-expanding Medtronic
CoreValve System, was studied. A number of patient
categories were excluded, which resulted in w35%
of all patients with the Medtronic CoreValve System
at the representative institutions being excluded.
An extremely important issue is the question “were
there speciﬁc reasons why these patients were ex-
cluded and what was the pacemaker rate in that
population?” The impact of this is not possible to
gauge but may be important. Of the 200 patients
actually enrolled, an additional 6 patients did not
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848receive the device, and then between implantation
and 30 days, 11 additional patients either died or
missed their follow-up endpoint (1 withdrew con-
sent), so that the percentage of patients actually
evaluated among patients treated is even smaller. A
permanent pacemaker was implanted in 24.4%
of patients, which, interestingly enough, is neither
mentioned in the abstract nor text but only found in
Table 3 (1). Importantly, the pacemaker was typi-
cally implanted during the hospital stay within the
ﬁrst 48 h. That has important implications for the
future because the duration of hospital stay is
decreasing. Beyond 48 h, there was no further
incidence of complete heart block, although other
conduction defects were seen. What will happen to
the patients with late-onset conduction defects is
not clear.
A critical portion of the paper relates to proce-
dural performance. The Medtronic CoreValve System
bioprosthesis “contains a self-expanding nitinol
frame with a high radial force that interacts with
tissues a few millimeters below the aortic annulus”
(1). Mechanical compression at that site sets the
stage for either temporary or permanent damage to
the conduction system. As could be imagined, either
local anatomic features such as excessive asymmet-
rical deposition of calciﬁc nodules or procedural
factors could affect the results and outcome of the
procedure. Important ﬁndings in this study included
implantation depth. By receiver-operating charac-
teristic analysis, the optimal implantation depth
was #4 mm, even though that was only able to be
achieved in 25.5% of the patients. That depth had
the best negative predictive value (93.9%), although
the positive predictive value was only 21.7%.
Accordingly, if that is an extremely important metric
of the procedure, it is only able to be achieved in a
minority of all patients and, as a goal, is less rele-
vant with this current prosthetic design. In addition,
smaller-sized devices were more frequently associ-
ated with higher rates of optimal implantation
depth, although a tradeoff may be that undersized
devices may result in more aortic regurgitation,
which, by itself, has a negative effect on longer-term
outcome. What is particularly concerning is that
despite speciﬁc instructions to trial participants
to adhere to Class I or II indications for pacemaker
implantation, only 18% of implantations wereactually for those indications; furthermore, despite
an optimal depth of valve implantation of #6 mm,
that was only achieved in 46% of patients. Both of
these issues raise concern about the importance and
relevance of the study’s conclusions and potential
application to widespread practice.
The discussion of this paper requires careful
attention. It is detailed in the analysis of the litera-
ture and the issues involved. The conclusions and
clinical perspectives are thoughtful and important.
The bottom line of this set of “twofers” is the fol-
lowing: 1) the twofer of pacemaker implantation
(and conduction defects including complete heart
block) occurring in the setting of TAVR is seen to
a variable degree depending in part on the spe-
ciﬁc bioprosthesis implanted; 2) whether this twofer
with a combination of pacemaker implantation and
TAVR is coded as a complication is important for
multiple reasons—patient education, reimbursement,
procedural performance, and guideline-based man-
agement of pacemaker implantation—any movement
to consider a permanent pacemaker not a compli-
cation of TAVR raises many concerns and could be
considered potentially disingenuous because in the
surgical literature on aortic valve replacement, the
need for a new pacemaker for heart block is clearly
coded as a complication; 3) technical details of pro-
cedural performance are important, but optimizing
device placement is difﬁcult with this speciﬁc de-
vice, even when directives are given at study ini-
tiation; 4) future technological iterations will be
focused on maximizing outcome but minimizing
“events” such as conduction defects and the need
for permanent pacemaker implantation. The current
device will continue to iterate and to be an impor-
tant device in this rapidly expanding ﬁeld. The need
to iterate to solve these issues requires acceptance of
the fact that such issues as the need for a “twofer”
with a pacemaker and a bioprosthesis should not be
considered an acceptable longer-term part of TAVR
but rather a need that should be addressed and
overcome.
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